Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



A blood test for MS? Expect one in late May

Six panels of an MRI scan

The medical toolbox for treating MS has progressed in leaps and bounds over the last two decades, as highlighted by the recent approval of  for the most severe and treatment-resistant form of the disease.

Despite this success, the underlying disease mechanisms and triggers are not well understood. This makes diagnosis a challenge — with very high stakes. The longer the disease progresses without treatment, the more irreversible neurological damage can be done.

To that end, Nashville, Tennesee-based IQuity will launch a first-of-its-kind blood test for MS in late May. The technology, originally licensed from Vanderbilt University, analyzes long non-coding RNA (lncRNA) in the patient’s blood to identify patterns indicative of the disease.

To our knowledge, we’re going to be the first blood-based RNA test for multiple sclerosis, and definitely among the first – if not the first – in the field of autoimmune diseases,” said Chase Spurlock,  and  of IQuity, via phone.

Spurlock said the test, dubbed IsolateMS, has proven accuracy greater than 90 percent. It can also deliver results in as little as seven days. What’s more, the disease markers were present at the earliest stages of the disease.

This was pretty exciting because, a lot of times, the molecular patterns that we can discern from the immune cells precede the physical manifestations of disease,” Spurlock stated.

By comparison, today’s diagnostic criteria actually include “the dissemination of space and time.” In other words, neurologists look for disease progression in successive MRI scans, combined with other tests such as lumbar punctures (spinal taps). It’s an invasive process that can take months or years, Spurlock noted.

That’s far from ideal. Some 80 percent of patients have a relapsing-remitting form of MS, characterized by cycles of disease remission and flares or “attacks” when the immune system does irreparable damage to the brain. By rapidly diagnosing the disease, physicians can intervene more aggressively to prevent a loss of function.  

Early scans paired with blood tests like ours would give more information to the provider that they have traditionally had,” Spurlock said, noting that it’s intended to be used in concert with tools such as MRIs for a faster, more definitive diagnosis.

A spokeswoman for the National MS Society said the organization is still working on its official guidelines for the test ahead of its upcoming launch.

The National MS Society is aware of this test, and in fact funded some of the research contributing to its development. However, before we provide information about it to the community, we will have our National Medical Advisory Committee evaluate how this fits in with the revised MS diagnostic guidelines which will be forthcoming later in 2017.”

Classified as a laboratory developed test (LDT), IsolateMS will not immediately be covered by insurers. CFO and CSO Julia Polk said the company has engaged a reimbursement consultancy firm to help the team build its case and early market research has uncovered a surprising source of clinical utility and value.

We never really considered that the diagnosed population of 400,000 Americans was a testable population for us,” Polk explained. “What we’ve learned is that many of the community neurologists are taking care of patients that they didn’t originally diagnose. And they have people in their practices that they just don’t believe have MS.”

Many patients have also questioned whether they really have the disease, she said, given the many overlaps between MS and other neurological conditions. According to Polk, the literature indicates misdiagnosis in MS is between 5-35 percent.

You do the math on that; around half of those will be on disease-modifying therapies,” she said. Given the drugs cost tens of thousands of dollars per year, between $0.5-3.5 billion may be spent annually on patients that don’t need the therapies. 

In the meantime, IQuity’s aim is to bring the price of the test down to $1,250 per test, “right around what a patient might pay for a second or third MRI when they have to pay out of pocket,” Polk said.

To say the company has many more shots on goal would be an understatement.  more autoimmune – or simply immune-related – conditions could be decoded using the machine-learning lncRNA approach.

Next in line is a test that seeks to distinguish between irritable bowel syndrome (IBS) and irritable bowel diseases such as Crohn’s disease and ulcerative colitis. It’s currently undergoing validation. 

A third, blood-based test for fibromyalgia is expected to reach the market in early fall. It will also look at rheumatoid arthritis and lupus to differentiate between the three diseases.

Both the IBS and fibromyalgia tests tap into a deep, global unmet need. Not only do patients struggle to find a diagnosis, many contend with providers who don’t believe the conditions are real. Until now, there haven’t been many definitive biological clues. But as with the MS diagnostic, IQuity is decoding molecular patterns that are many layers deeper than what patients and providers can observe in a doctor’s office.

There is also room to expand on the MS test.

Story Source: The above story is based on materials provided by MEDCITYNEWS
Note: Materials may be edited for content and length

Go to Newer News Go to Older News